Enzo Biochem, Inc. Quarterly report pursuant to Section 13 or 15(d)

Segment reporting (Tables)

9 Months Ended

Apr. 30, 2017

The following financial information represents the operating results of the reportable segments of the Company:

	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	19,584			—			—			—		$	19,584
Product revenues		—		$	7,312			—			—			7,312
Royalty and license fee income		—			193			—			—			193
		19,584			7,505			—			—			27,089
Operating costs and expenses:
Cost of clinical laboratory services		11,334			—			—			—			11,334
Cost of product revenues		—			3,582			—			—			3,582
Research and development		—			552		$	214			—			766
Selling, general and administrative		6,118			2,745			—		$	1,639			10,502
Provision for uncollectible accounts receivable		650			(30	)		—			—			620
Legal fee expense		4			42			—			466			512
Total operating costs and expenses		18,106			6,891			214			2,105			27,316

Operating income (loss)		1,478			614			(214	)		(2,105	)		(227	)

Other income (expense):
Interest		(28	)		12			—			131			115
Other		7			(98	)		—			17			(74	)
Foreign exchange loss		—			147			—			—			147
Income (loss) before income taxes	$	1,457		$	675		$	(214	)	$	(1,957	)	$	(39	)

Depreciation and amortization included above	$	390		$	423		$	—		$	37		$	850

Share-based compensation included in above:
Cost of clinical laboratory services	$	2			—			—			—		$	2
Selling, general and administrative		38		$	23			—		$	146			207
Total	$	40		$	23		$	—		$	146		$	209

Capital expenditures	$	483		$	252		$	—		$	—		$	735

	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	18,162			—			—			—		$	18,162
Product revenues		—		$	8,001			—			—			8,001
Royalty and license fee income		—			270			—			—			270
		18,162			8,271			—			—			26,433
Operating costs and expenses:
Cost of clinical laboratory services		11,142			—			—			—			11,142
Cost of product revenues		—			3,846			—			—			3,846
Research and development		—			674		$	208			—			882
Selling, general and administrative		6,008			2,877			—		$	1,984			10,869
Provision for uncollectible accounts receivable		612			(36	)		—			—			576
Legal fee expense		54			11			—			1,567			1,632
Legal settlements, net		—			—			—			—			—
Total operating costs and expenses		17,816			7,372			208			3,551			28,947

Operating income (loss)		346			899			(208	)		(3,551	)		(2,514	)

Other income (expense)
Interest		(33	)		7			—			(14	)		(40	)
Other		2			4			—			16			22
Foreign exchange loss		—			419			—			—			419
Income (loss) before income taxes	$	315		$	1,329		$	(208	)	$	(3,549	)	$	(2,113	)

Depreciation and amortization included above	$	418		$	514		$	—		$	28		$	960

Share-based compensation included in above:
Cost of clinical laboratory services	$	2			—			—			—		$	2
Selling, general and administrative		14		$	9			—		$	124			147
Total	$	16		$	9		$	—		$	124		$	149

Capital expenditures	$	331		$	115		$	—		$	—		$	446

	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	56,979			—			—			—		$	56,979
Product revenues		—		$	21,721			—			—			21,721
Royalty and license fee income		—			933			—			—			933
		56,979			22,654			—			—			79,633
Operating costs and expenses:
Cost of clinical laboratory services		33,282			—			—			—			33,282
Cost of product revenues		—			10,411			—			—			10,411
Research and development		—			1,695		$	376			—			2,071
Selling, general and administrative		17,967			8,596			—		$	6,578			33,141
Provision for uncollectible accounts receivable		1,910			58			—			—			1,968
Legal fee expense		105			70			—			1,079			1,254
Total operating costs and expenses		53,264			20,830			376			7,657			82,127

Operating income (loss)		3,715			1,824			(376	)		(7,657	)		(2,494	)

Other income (expense):
Interest		(85	)		34			—			291			240
Other		126			(98	)		—			41			69
Foreign exchange loss		—			(308	)		—			—			(308	)
Income (loss) before income taxes	$	3,756		$	1,452		$	(376	)	$	(7,325	)	$	(2,493	)

Depreciation and amortization included above	$	1,185		$	1,432		$	—		$	75		$	2,692

Share-based compensation included in above:
Cost of clinical laboratory services	$	5			—			—			—		$	5
Selling, general and administrative		74		$	49			—		$	473			596
Total	$	79		$	49		$	—		$	473		$	601

Capital expenditures	$	1,070		$	354		$	—		$	—		$	1,424

	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	52,775			—			—			—		$	52,775
Product revenues		—		$	22,266			—			—			22,266
Royalty and license fee income		—			1,129			—			—			1,129
		52,775			23,395			—			—			76,170
Operating costs, expenses and legal settlements, net:
Cost of clinical laboratory services		32,009			—			—			—			32,009
Cost of product revenues		—			10,663			—			—			10,663
Research and development		—			2,002		$	608			—			2,610
Selling, general and administrative		16,943			8,709			—		$	6,722			32,374
Provision for uncollectible accounts receivable		1,787			(48	)		—			—			1,739
Legal fee expense		120			(6	)		—			5,530			5,644
Legal settlements, net		1,500			(19,950	)		—			—			(18,450	)
Total operating costs, expenses and legal settlements, net		52,359			1,370			608			12,252			66,589

Operating income (loss)		416			22,025			(608	)		(12,252	)		9,581

Other income (expense)
Interest		(75	)		38			—			(85	)		(122	)
Other		5			35			—			47			87
Foreign exchange loss		—			(99	)		—			—			(99	)
Income (loss) before income taxes	$	346		$	21,999		$	(608	)	$	(12,290	)	$	9,447

Depreciation and amortization included above	$	1,226		$	1,568		$	—		$	68		$	2,862

Share-based compensation included in above:
Cost of clinical laboratory services	$	5			—			—			—		$	5
Selling, general and administrative		33		$	19			—		$	313			365
Total	$	38		$	19		$	—		$	313		$	370

Capital expenditures	$	1,122		$	267		$	—		$	—		$	1,389